Fundamental research on the development of treatment for triple negative breast cancer
Fundamental research on the development of treatment for triple negative breast cancer
批准号:
20591561
负责人:
KUREBAYASHI Junichi
金额:
$2.66万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2010
中文摘要
临床常规测量乳腺癌组织中雌激素受体、孕激素受体和HER2的表达水平,以预测对内分泌治疗和抗HER2治疗的反应。不表达这三种受体的乳腺肿瘤被称为三阴性乳腺癌(TNBC)。TNBC对内分泌治疗和抗her2治疗均无反应,具有生物侵袭性,易于早期复发,预后差。这些发现促使我们开发针对TNBC的新治疗策略。首先,我们在一组人类乳腺癌细胞系中研究了与TNBC特征相关的各种基因的蛋白质表达谱。接下来,我们在乳腺癌细胞系面板上研究了dna损伤细胞毒性药物和分子靶向药物诱导的抗肿瘤活性、对细胞周期进程、细胞凋亡和肿瘤干细胞群的影响。这些实验结果表明,Src信号抑制剂达沙替尼和dna损伤剂依托泊苷对基底B亚型乳腺癌细胞具有较强的抗肿瘤作用,分别与达沙替尼阻断G1-S并诱导凋亡或依托泊苷阻滞G2/M并诱导凋亡有关。这是第一次表明,达沙替尼减少了假定的癌症干细胞的比例。我们还利用免疫组织化学研究了乳腺癌患者Src信号激活的临床意义。本研究结果表明,Src信号的激活可能会增加乳腺癌细胞的转移潜能。
英文摘要
Expression levels of estrogen receptor, progesterone receptor and HER2 in breast cancer tissues have been routinely measured in clinics to predict responses to endocrine therapy and anti-HER2 therapy. Breast tumors expressing none of these three receptors are named as triple negative breast cancer (TNBC). TNBC responds to neither endocrine therapy nor anti-HER2 therapy, is biologically aggressive, tends to recur earlier, and renders a poor prognosis. These findings prompt us to develop new treatment strategies against TNBC. First, we investigated a protein expression profile of various genes related to TNBC characteristics in a panel of human breast cancer cell lines. Next, we studied antitumor activity, effects on cell cycle progression, apoptosis and cancer stem cell population induced by DNA-damaging cytotoxic agents and molecular targeting agents in the panel of breast cancer cell lines. These experimental results have revealed that a Src signal inhibitor, dasatinib and a DNA-damaging agent, etoposide show potent antitumor effect on breast cancer cells of basal B subtype associated with G1-S blockade and induction of apoptosis for dasatinib or G2/M retardation and induction of apoptosis for etoposide, respectively. It is indicated for the first time that dasatinib reduces a proportion of putative cancer stem cells. We also investigated clinical significance of activation of Src signaling using immunohistochemistry in patients with breast cancer. The results of this study have indicated that activation of Src signaling may increase metastatic potential of breast cancer cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer : a phase I dose-finding study by the Kinki Breast Cancer Study Group.
卡培他滨和紫杉醇联合化疗治疗不能手术或复发性乳腺癌:近畿乳腺癌研究组的 I 期剂量探索研究。
DOI:
--
发表时间:
2008
期刊:
Cancer Chemother Pharmacol 61
影响因子:
--
作者:
[Masuda N, et al.]
通讯作者:
et al.
トリプルネガティブ乳癌の薬物療法に関する基礎的検討.
三阴性乳腺癌药物治疗的基本综述。
DOI:
--
发表时间:
2008
期刊:
影响因子:
--
作者:
[紅林淳一, 他]
通讯作者:
他
みんなに役立つ乳癌の基礎と臨床
对每个人都有用的乳腺癌基础知识和临床信息
DOI:
--
发表时间:
2009
期刊:
影响因子:
--
作者:
[神代理史, 相馬佳絵, 中島由佳, 山口ゆり, 川野輪香織, 木村圭志, 黒住昌史, 林慎一, 柳澤純, 林 慎一, 林慎一]
通讯作者:
林慎一
The cell cycle profile (C2P) test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy.
细胞周期谱(C2P)测试是接受术后5-氟尿嘧啶化疗的乳腺癌患者的预后指标。
DOI:
--
发表时间:
2011
期刊:
Jpn J Clin Oncol. 27(Epub ahead of print)
影响因子:
--
作者:
[Kurebayashi J, Moriya T, et al.]
通讯作者:
et al.
Preclinical rationale for combined treatments of endocrine therapy with 5-fluorouracil but with neither doxorubicin nor paclitaxel in the treatment of endocrine responsive breast cancer.
内分泌治疗与 5-氟尿嘧啶但既不与阿霉素也不与紫杉醇联合治疗内分泌反应性乳腺癌的临床前基本原理。
DOI:
--
发表时间:
2010
期刊:
Cancer Chemother Pharmacol 65
影响因子:
--
作者:
[Kurebayashi J, et al.]
通讯作者:
et al.
共 33 条
Experimental research on the development of new treatment strategies for triple negative breast cancer
-
批准号:23591911
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.24万
-
财政年份:2011
-
负责人:KUREBAYASHI Junichi
-
依托单位:
EXPERIMENTAL STUDY ON ACTION MECHANISMS OF RESISTANCE TO HORMONAL THERAPY AND OVERCOMING THIS RESISTANCE IN BREAST CANCER
-
批准号:14571166
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.79万
-
财政年份:2002
-
负责人:KUREBAYASHI Junichi
-
依托单位:
Establishment of a postsurgical micro-metastasis model of breast cancer and development of new postsurgical adjuvant therapies
-
批准号:08671401
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1996
-
负责人:KUREBAYASHI Junichi
-
依托单位:
Analysis of antiinvasive and antimetastatic effects of antimetasatic agents and cytotoxic drugs in a metastasis model of human breast cancer
-
批准号:06671233
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$0.26万
-
财政年份:1994
-
负责人:KUREBAYASHI Junichi
-
依托单位: